AbbVie Raises Fiscal Year Guidance on Immunology, Neuroscience Growth

Published: 2026-04-29 08:39:27 ET ABBV

Published on 04/29/2026 at 08:39 am EDT

By Nicholas G. Miller

AbbVie raised its full-year adjusted earnings guidance and reported higher first-quarter revenue, boosted by growth in its immunology and neuroscience portfolios.

Revenue rose 12% to $15 billion, helped by 16% growth in the company's immunology portfolio and a 26% increase in neuroscience revenue. Wall Street expected $14.72 billion, according to FactSet.

AbbVie's immunology portfolio was led by arthritis and Crohn's disease drugs Skyrizi and Rinvoq , for which revenue rose 31% and 23% respectively. That offset a 39% decline for immune-disease therapy Humira, which is facing competition from cheaper copycats.

The company boosted its full-year adjusted earnings outlook to $14.08 to $14.28 a share, up from its previous forecast of $13.96 to $14.16 a share. Wall Street sees adjusted earnings of $14.12 a share.

For the first-quarter, the company posted net income of $695 million, or 39 cents a share, down from $1.29 billion, or 72 cents a share, the year prior.

Adjusted earnings were $2.65 a share. Analysts polled by FactSet expected $2.59 a share.

Write to Nicholas G. Miller at [email protected].

(END) Dow Jones Newswires

04-29-26 0838ET